West Pharmaceutical (NYSE: WST) CEO granted new RSUs and stock options

Rhea-AI Filing Summary

Green Eric Mark reported acquisition or exercise transactions in this Form 4 filing.

West Pharmaceutical Services reported that President, CEO and Board Chair Eric Mark Green received new equity awards. On March 1, 2026, he was granted 6,986 restricted stock units, each representing a contingent right to receive one share of WST common stock.

On the same date, he was also granted 16,630 stock options to buy WST common stock. Both the restricted stock units and the stock options vest in four equal annual installments beginning on March 1, 2027, tying the awards to multi‑year service and performance at the company.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Green Eric Mark

Role President, CEO and Board Chair

Type	Security	Shares	Price	Value
Grant/Award	Rst. Stock Unit	6,986	$0.00	--
Grant/Award	Stock Option (Right to Buy)	16,630	$0.00	--

Holdings After Transaction: Rst. Stock Unit — 6,986 shares (Direct); Stock Option (Right to Buy) — 16,630 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of WST common stock. The restricted stock units vest in four equal annual installments beginning on March 1, 2027. The stock option vests in four equal annual installments beginning on March 1, 2027.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Green Eric Mark

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PA 19341

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO and Board Chair

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Rst. Stock Unit	(1)	03/01/2026		A		6,986		(2)	(2)	Common Stock	6,986	$0	6,986	D
Stock Option (Right to Buy)	$254.34	03/01/2026		A		16,630		(3)	03/01/2036	Common Stock	16,630	$0	16,630	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of WST common stock.

2. The restricted stock units vest in four equal annual installments beginning on March 1, 2027.

3. The stock option vests in four equal annual installments beginning on March 1, 2027.

	/s/ Caitlin Hippeli, as an agent for Eric Green	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did WST CEO Eric Mark Green report on this Form 4?

Eric Mark Green reported two equity award grants from West Pharmaceutical Services. He received 6,986 restricted stock units and 16,630 stock options on March 1, 2026, both structured as derivative securities tied to WST common stock.

How many restricted stock units did the WST CEO receive in this filing?

The CEO received 6,986 restricted stock units. Each unit represents a contingent right to one share of West Pharmaceutical Services common stock, providing future share-based compensation that depends on continued service and satisfaction of the vesting schedule.

When do Eric Mark Green’s new WST restricted stock units vest?

The restricted stock units vest in four equal annual installments beginning on March 1, 2027. This schedule spreads the potential share delivery over four years, encouraging longer-term alignment between the CEO and West Pharmaceutical Services shareholders.

What stock option grant was reported for the WST CEO on March 1, 2026?

Eric Mark Green was granted 16,630 stock options on March 1, 2026. These options give him the right to buy WST common shares and, like the restricted stock units, vest in four equal annual installments starting March 1, 2027.

Are the WST CEO’s new equity awards direct or indirect holdings?

The filing classifies both awards as direct ownership. The Form 4 indicates direct beneficial ownership (coded “D”) for the 6,986 restricted stock units and 16,630 stock options reported in this insider transaction disclosure.

Does this WST Form 4 involve insider buying or selling on the open market?

No open market buying or selling is shown. The Form 4 reports grant or award acquisitions of restricted stock units and stock options, both at a reported transaction price of 0.0000, reflecting compensation awards rather than market trades.